Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 10;16(12):530.
doi: 10.3390/toxins16120530.

Botulinum Toxin and Migraine: Goals and Perspectives

Maria Pia Prudenzano  1
Affiliations
Editorial

Botulinum Toxin and Migraine: Goals and Perspectives

Maria Pia Prudenzano. Toxins (Basel). .

Abstract

This Special Issue aims to provide an updated overview of the current state and future perspectives of botulinum toxin treatment for migraine [...].

PubMed Disclaimer

Conflict of interest statement

The author declares receiving honoraria for consulting from AbbVie, Teva, Lundbeck, Novartis, Eli Lilly, Lundbeck, Novartis, and Pfizer outside of the submitted work.

References

    1. Dodick D.W. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018;58:4–16. doi: 10.1111/head.13300. - DOI - PubMed
    1. Iyengar S., Johnson K.W., Ossipov M.H., Aurora S.K. CGRP and the Trigeminal System in Migraine. Headache. 2019;59:659–681. doi: 10.1111/head.13529. - DOI - PMC - PubMed
    1. Becker W.J. Botulinum Toxin in the Treatment of Headache. Toxins. 2020;12:803. doi: 10.3390/toxins12120803. - DOI - PMC - PubMed
    1. Zhang X., Strassman A.M., Novack V., Brin M.F., Burstein R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle? Cephalalgia. 2016;36:875–886. doi: 10.1177/0333102416636843. - DOI - PMC - PubMed
    1. Cohen F., Yuan H., De Poy E.M.G., Silberstein S.D. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine. Neurotherapeutics. 2022;19:922–930. doi: 10.1007/s13311-022-01230-x. - DOI - PMC - PubMed

Publication types

LinkOut - more resources